Got 90 seconds? Then listen to Chairman, Paul Rennie tell us about their company news.

Neuroscientific biopharmaceuticals (ASX:NSB) is an Australian biotechnology company developing novel disease modifying therapies for neurodegenerative disease such as Alzheimer’s, Multiple Sclerosis as well as ophthalmology indications caused by degeneration of the optic nerve.

Neuroscientific is currently finishing an IND enabling preclinical safety and toxicology program with its US partners and will be initiating first in human clinical studies later this year.

We gave Paul Rennie, Chairman of Neuroscientific, 90 seconds to tell us more about the recent announcement.

Have a good idea for our next 90 Seconds With segment? Email us at [email protected]